Ten million new cases of HIV projected amid global reduction in funding
New HIV infections have declined by 39% since 2010, from 2.1 million to 1.3 million in 2023, according to UNAIDS.…
All articles by GlobalData Healthcare
GlobalData Healthcare
-
-
AD/PD 2025: Further evidence for efficacy of TauRx’s LMTX, despite lack of true placebo comparator
On 5 April 2025 at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, held in Vienna, Austria, during…
-
AD/PD 2025: Long-term data shows Anavex’s Blarcamesine benefits in early Alzheimer’s
On 5 April 2025, at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases held in Vienna, Austria, during…
-
AD/PD 2025: Spotlight on ARIA as new data and evidence emerges for Alzheimer’s DMT use
Following the launch of the first disease-modifying therapies (DMTs) for Alzheimer’s disease (AD), a key theme at the AD/PD 2025…
-
AD/PD 2025: Roche’s Brainshuttle technology promises next generation of amyloid beta mAbs
At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium…
-
AD/PD 2025: Cerevance’s Solengepras falls short of primary endpoint in ASCEND trial
On 2 April, at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Disease, Cerevance announced that solengepras failed to…
-
AD/PD 2025: Roche highlights time-to-event for assessing prasinezumab in early PD
At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Roche announced topline results of prasinezumab in patients…
-
AD/PD 2025: Buntanetap shows promise in early Parkinson’s with mild dementia
At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD), Annovis Bio announced data from its six-month, randomised,…
-
AD/PD 2025: Alzheon’s ALZ-801 shows promise for MCI but missed in mild Alzheimer’s
On 1 April, at the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases, during a symposium sponsored by Alzheon,…
-
ACC 2025: AZD0780 shows significant LDL-C reduction in PURSUIT Phase IIb trial
On 31 March, at the American College of Cardiology (ACC) Annual Scientific Session & Expo in Chicago, US, the findings…
